Jnana Therapeutics ^Partner

Jnana Therapeutics is a clinical-stage biotechnology company based in Boston, focused on small molecule drug discovery. Utilizing its proprietary RAPID chemoproteomics platform, Jnana aims to address significant medical needs by targeting challenging proteins involved in various diseases, including rare genetic disorders and immune-mediated conditions. The company was acquired by Otsuka Pharmaceutical in September 2024, which enhances its ability to develop therapies through clinical stages.

The RAPID platform enables the identification of unique binding sites on protein targets, facilitating the discovery of small molecule therapies. This innovative approach allows Jnana to tackle targets that have traditionally been difficult to drug. The company is advancing its pipeline with JNT-517, an oral therapy for phenylketonuria (PKU), and is developing preclinical candidates for immune-mediated diseases. Jnana collaborates with notable investors and pharmaceutical partners, positioning itself strongly within the biotechnology landscape.